FDA places TKM-Ebola trial on clinical hold

The FDA notifies Tekmira Pharmaceuticals (TKMR) that its Phase 1 healthy volunteer clinical trial for TKM-Ebola is on clinical hold until the agency receives additional data related to the mechanism of cytokine release observed at higher doses. Once resolved, the trial may proceed to the ascending dose phase of the study.

The company is conducting the trial to assess the safety, tolerability and pharmacokinetics of TKM-Ebola in healthy adult volunteers without administering any steroid pre-medications.

Shares are down 20% premarket but only on turnover of 300 shares.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs